6-氯-2-吡啶羧酸乙酯 | 21190-89-6

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 6-氯-2-吡啶羧酸乙酯
• 中文别名: 6-氯吡啶-2-甲酸乙酯
• 英文名称: ethyl 6-chloropicolinate
• 英文别名: ethyl 6-chloropyridine-2-carboxylate；6-chloropyridine-2-carboxylic acid ethyl ester
• CAS: 21190-89-6
• 化学式: C₈H₈ClNO₂
• mdl: MFCD09878438
• 分子量: 185.61
• InChiKey: ORSVWYSFUABOQU-UHFFFAOYSA-N

物化性质

• 沸点：
  289℃
• 密度：
  1.245
• 闪点：
  129℃

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  39.2
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2933399090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Ethyl 6-chloropicolinate
Product Name:
Synonyms: Ethyl 6-chloro-2-pyridinecarboxylate

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
Wear protective gloves/protective clothing/eye protection/face protection
P280:
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P304+P340: IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing
P405: Store locked up

---

Section 3. Composition/information on ingredients.
Ethyl 6-chloropicolinate
Ingredient name:
CAS number: 21190-89-6

---

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.
Ingestion:

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C8H8ClNO2
Molecular weight: 185.6

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  6-氯-2-吡啶羧酸乙酯 在 N-甲基吗啉 、 1,1'-双(二苯基膦)二茂铁 、 四(三苯基膦)钯 、 lithium hydroxide monohydrate 、 potassium carbonate 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 四氢呋喃 、 甲醇 、 水 、 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 36.0h， 生成 (S)-6-(4-chlorophenyl)-N-(2-(2-cyano-4,4-difluoropyrrolidin-1-yl)-2-oxoethyl)picolinamide
  参考文献：
  名称：

  Identification of BR102910 as a selective fibroblast activation protein (FAP) inhibitor

  摘要：

  DOI：

  10.1016/j.bmcl.2021.127846
• 作为产物：
  描述：

  6-氯吡啶-2-羧酸 在 氯化亚砜 、 三乙胺 作用下， 以 1,4-二氧六环 、 乙醇 、 水 为溶剂， 以8.82 g (91%)的产率得到6-氯-2-吡啶羧酸乙酯
  参考文献：
  名称：

  1,4-disubstituted piperazines

  摘要：

  本发明涉及一般式为##STR1##的1,4-二取代哌嗪，其中X、Y、Z、R.sup.1、R.sup.2和r如本说明书详细部分所定义，或其盐，以及它们的制备方法、含有它们的组合物，以及它们用于临床治疗疼痛、高敏感和/或炎症症状的用途，其中C-纤维通过诱导神经源性疼痛或炎症发挥病理生理作用，以及它们用于治疗由胰岛素拮抗肽的分泌和循环引起或相关的适应症，例如非胰岛素依赖性糖尿病（NIDDM）和与衰老相关的肥胖症。

  公开号：

  US05916889A1

文献信息

• Pd-Catalyzed Vinylation of Aryl Halides with Inexpensive Organosilicon Reagents Under Mild Conditions
  作者：Chu-Ting Yang、Jun Han、Jun Liu、Yi Li、Fan Zhang、Hai-Zhu Yu、Sheng Hu、Xiaolin Wang

  DOI：10.1002/chem.201802573

  日期：2018.7.20

  Pd‐catalyzed Hiyama vinylation reaction of non‐activated aryl chlorides and bromides under mild conditions was developed. The use of efficient vinyl donors and electron‐rich sterically hindered phosphine ligands was critical for the success of the reaction. The products of this transformation can be used for Am/Cm separation, an important challenge in nuclear fuel reprocessing. The substituent effect

  在温和条件下开发了钯催化未活化的芳基氯和溴化物的Hiyama乙烯基化反应。有效的乙烯基供体和富含电子的位阻膦配体的使用对于反应成功至关重要。这种转化的产物可用于Am / Cm分离，这是核燃料后处理中的一项重要挑战。还获得了取代基对Am / Cm分离选择性的影响，这可能有助于开发用于分离Am和Cm的新型色谱材料。
• [EN] 6,7-DIHYDRO-5H-PYRIDO[2,3-C]PYRIDAZINE DERIVATIVES AND RELATED COMPOUNDS AS BCL-XL PROTEIN INHIBITORS AND PRO-APOPTOTIC AGENTS FOR TREATING CANCER<br/>[FR] DÉRIVÉS DE 6,7-DIHYDRO-5H-PYRIDO[2,3-C]PYRIDAZINE ET COMPOSÉS APPARENTÉS EN TANT QU'INHIBITEURS DE PROTÉINE BCL-XL ET AGENTS PRO-APOPTOTIQUES POUR LE TRAITEMENT DU CANCER
  申请人：SERVIER LAB

  公开号：WO2021018858A1

  公开（公告）日：2021-02-04

  The present invention discloses 6,7-dihydro-5H-pyrido[2,3- c]pyridazine, 1,2,3,4-tetrahydroquinoline, 1H-indole, 3,4- dihydro-2H-1,4-benzoxazine, 1H-pyrrolo[2,3-b]pyridin-1-yl, 7H- pyrrolo[2,3-c]pyridazine, 5H,6H,7H,8H,9H-pyridazino[3,4-b]azepine derivatives and related compounds of formula (I) as Bcl-xL protein inhibitors for use as pro-apoptotic agents for treating cancer, autoimmune diseases or immune system diseases. Formula (I). The description discloses the preparation of exemplary compounds (e.g. pages 113 to 354 examples 1 to 221) as well as pharmacological studies with relevant data (e.g. pages 355 to 367; examples A to E; tables 1 to 5). Exemplary compounds are e.g. 2-6-[(1,3-benzothiazol-2-yl) amino]-1,2,3,4-tetrahydroquinolin-1-yl}-1,3-thiazole-4-carboxylic acid (example 1) or e.g. 3-1-[(adamantan-1-yl)methyl]-5- methyl-1H-pyrazol-4-yl}-6-3-[(1,3-benzothiazol-2-yl)amino]-4- methyl-5H,6H,7H,8H-pyrido[2,3-c]pyridazin-8-yl]pyridine-2-carboxylic acid (example 24).

  本发明公开了作为Bcl-xL蛋白抑制剂用于治疗癌症、自身免疫疾病或免疫系统疾病的促凋亡剂的6,7-二氢-5H-吡啶并[2,3-c]吡啶嗪、1,2,3,4-四氢喹啉、1H-吲哚、3,4-二氢-2H-1,4-苯并噁嗪、1H-吡咯并[2,3-b]吡啶-1-基、7H-吡咯并[2,3-c]吡啶嗪、5H,6H,7H,8H,9H-吡啶并[3,4-b]氮杂环庚烷衍生物和相关化合物的化学式(I)。描述了示例化合物的制备（例如第113至354页的示例1至221）以及具有相关数据的药理学研究（例如第355至367页；示例A至E；表1至5）。示例化合物包括例如2-6-[(1,3-苯并噻唑-2-基)氨基]-1,2,3,4-四氢喹啉-1-基}-1,3-噻唑-4-羧酸（示例1）或例如3-1-[(1-金刚烷-1-基)甲基]-5-甲基-1H-吡唑-4-基}-6-3-[(1,3-苯并噻唑-2-基)氨基]-4-甲基-5H,6H,7H,8H-吡啶并[2,3-c]吡啶-8-基]吡啶-2-羧酸（示例24）。
• Synthesis of Functionalized Pyridines via a Regioselective Oxazoline Promoted C–H Amidation Reaction
  作者：Tracy M. M. Maiden、Stephen Swanson、Panayiotis A. Procopiou、Joseph P. A. Harrity

  DOI：10.1021/acs.orglett.6b01612

  日期：2016.7.15

  The first Rh-catalyzed C–H amidation of pyridines is reported. The incorporation of a substituent at the C2 position both is crucial to the success of this transformation and provides considerable scope for further elaboration of the resulting products. Among these compounds, 2-chloropyridines allow access to a selection of intermediates including a versatile azaquinazoline scaffold.

  据报道，吡啶第一次被Rh催化的C–H酰胺化反应。在C 2位上引入取代基不仅对这种转化的成功至关重要，而且为进一步精制所得产物提供了相当大的范围。在这些化合物中，2-氯吡啶允许使用各种中间体，包括通用的氮杂喹唑啉骨架。
• Modular Syntheses of Star-Shaped Pyridine, Bipyridine, and Terpyridine Derivatives by Employing Sonogashira Reactions
  作者：Daniel Trawny、Valentin Kunz、Hans-Ulrich Reissig

  DOI：10.1002/ejoc.201402778

  日期：2014.10

  a series of star-shaped pyridine, bipyridine, and terpyridine derivatives is reported by using a modular approach that combines the use of a ligand, spacer, and core unit. A fairly efficient method to prepare 4′-nonafloxy-functionalized terpyridine derivatives is described. The building blocks that contain the functionalized pyridine, bipyridine, or terpyridine derivatives were linked to different

  通过使用结合使用配体、间隔基和核心单元的模块化方法，报告了一系列星形吡啶、联吡啶和三联吡啶衍生物的简单而灵活的合成。描述了一种相当有效的方法来制备 4'-nonafluxy 官能化的三联吡啶衍生物。包含功能化吡啶、联吡啶或三联吡啶衍生物的结构单元与不同的 C3 对称核心单元相连。在大多数情况下，Sonogashira 反应用于合成的关键最后步骤。星形十二氟化合物也以简单的方式制备。介绍了一种制备部分甲硅烷基化 1,3,5-三乙炔苯衍生物的简单程序，它提供了一种 C2 对称星形化合物的方法，该化合物只有一个三联吡啶和两个三联苯单元作为“虚拟”配体。系统地研究了完全共轭的 C3 对称吡啶衍生物的吸收和发射光谱，并观察到相当大的斯托克斯位移。
• [EN] SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1,2-a]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS<br/>[FR] COMPOSÉS N-(1H-INDAZOL-4-YL)IMIDAZO[1,2-A]PYRIDINE-3-CARBOXAMIDES SUBSTITUÉS EN TANT QU'INHIBITEURS DE TYROSINE KINASE DE RÉCEPTEURS DE TYPE III
  申请人：ARRAY BIOPHARMA INC

  公开号：WO2012082689A1

  公开（公告）日：2012-06-21

  Compounds of Formula I: and pharmaceutically acceptable salts thereof in which R1, R2, R3, R4, R5 and R6 have the meanings given in the specification, are inhibitors of cFMS and are useful in the treatment of fibrosis, bone-related diseases, cancer, autoimmune disorders, inflammatory diseases, cardiovascular diseases, pain and burns in a mammal.

  公式I的化合物及其药学上可接受的盐，在其中R1、R2、R3、R4、R5和R6具有规范中给定的含义，是cFMS的抑制剂，并且在治疗哺乳动物的纤维化、与骨相关的疾病、癌症、自身免疫性疾病、炎症性疾病、心血管疾病、疼痛和烧伤方面是有用的。